Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder

World Journal of Urology

Volumn 32, Issue 6, 2014, Pages 1485-1492

  Ebbing, Jan ^a,c   Mathia, Susanne ^a   Seibert, Felix S ^a,b   Pagonas, Nikolaos ^a,b   Bauer, Frederic ^a,b   Erber, Barbara ^a   Günzel, Karsten ^a   Kilic, Ergin ^a   Kempkensteffen, Carsten ^a   Miller, Kurt ^a   Bachmann, Alexander ^c   Rosenberger, Christian ^a   Zidek, Walter ^a   Westhoff, Timm H ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Bladder cancer; Calgranulin; Calprotectin; Leukocyte L1 antigen complex; Tumor marker; Urothelial carcinoma

Indexed keywords

CALGRANULIN; TUMOR MARKER;

AGED; CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; KIDNEY TUMOR; MALE; MIDDLE AGED; PREDICTIVE VALUE; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; URINARY BLADDER NEOPLASMS; URINE; UROTHELIUM;

AGED; CARCINOMA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY NEOPLASMS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84912037857     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-013-1227-8     Document Type: Article

References (17)

1. Ploeg M, Aben KKH, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27:289–293. doi:10.1007/s00345-009-0383-3
2. Lotan Y, Roehrborn CG (2003) Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61:109–118; discussion 118
3. Yafi FA, Brimo F, Auger M, Aprikian A, Tanguay S, Kassouf W (2013) Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer. Urol Oncol. doi:10.1016/j.urolonc.2012.09.011
4. Mitra AP, Cote RJ (2010) Molecular screening for bladder cancer: progress and potential. Nat Rev Urol 7:11–20. doi:10.1038/nrurol.2009.236
5. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Rouprêt M, Shariat SF, Zlotta AR (2011) Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 60:484–492. doi:10.1016/j.eururo.2011.05.053
6. Minami S, Sato Y, Matsumoto T, Kageyama T, Kawashima Y, Yoshio K, Ishii J-I, Matsumoto K, Nagashio R, Okayasu I (2010) Proteomic study of sera from patients with bladder cancer: usefulness of S100A8 and S100A9 proteins. Cancer Genomics Proteomics 7:181–189
7. Kim S-K, Kim E-J, Leem S-H, Ha Y-S, Kim Y-J, Kim W-J (2010) Identification of S100A8-correlated genes for prediction of disease progression in non-muscle invasive bladder cancer. BMC Cancer 10:21. doi:10.1186/1471-2407-10-21
8. Seibert FS, Pagonas N, Arndt R, Heller F, Dragun D, Persson P, Schmidt-Ott K, Zidek W, Westhoff TH (2013) Calprotectin and neutrophil gelatinase-associated lipocalin in the differentiation of pre-renal and intrinsic acute kidney injury. Acta Physiol Oxf Engl 207:700–708. doi:10.1111/apha.12064
9. Heller F, Frischmann S, Grünbaum M, Zidek W, Westhoff TH (2011) Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury. Clin J Am Soc Nephrol (CJASN) 6:2347–2355. doi:10.2215/CJN.02490311
10. Rosenberger C, Mandriota S, Jürgensen JS, Wiesener MS, Hörstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt K-U (2002) Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol (JASN) 13:1721–1732
11. Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 86:557–566. doi:10.1189/jlb.1008647
12. Gebhardt C, Németh J, Angel P, Hess J (2006) S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 72:1622–1631. doi:10.1016/j.bcp.2006.05.017
13. Gebhardt C, Breitenbach U, Tuckermann JP, Dittrich BT, Richter KH, Angel P (2002) Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis. Oncogene 21:4266–4276. doi:10.1038/sj.onc.1205521
14. Grebhardt S, Veltkamp C, Ströbel P, Mayer D (2012) Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer. Int J Cancer J Int Cancer 131:2785–2794. doi:10.1002/ijc.27591
15. Hemmerlein B, Markus A, Wehner M, Kugler A, Zschunke F, Radzum HJ (2000) Expression of acute and late-stage inflammatory antigens, c-fms, CSF-1, and human monocytic serine esterase 1, in tumor-associated macrophages of renal cell carcinomas. Cancer Immunol Immunother CII 49:485–492
16. Pilchowski R, Stöhr R, von Eggeling F, Hartmann A, Wunderlich H, Junker K (2011) Specific protein patterns characterize metastatic potential of advanced bladder cancer. J Urol 186:713–720. doi:10.1016/j.juro.2011.03.124
17. Ortega FJ, Sabater M, Moreno-Navarrete JM, Pueyo N, Botas P, Delgado E, Ricart W, Frühbeck G, Fernández-Real JM (2012) Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. Eur J Endocrinol Eur Fed Endocr Soc 167:569–578. doi:10.1530/EJE-12-0374